Literature DB >> 25957826

Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians.

Casey Lynnette Overby1, Emily Beth Devine2, Neil Abernethy3, Jeannine S McCune4, Peter Tarczy-Hornoch5.   

Abstract

To facilitate personalized drug dosing (PDD), this pilot study explored the communication effectiveness and clinical impact of using a prototype clinical decision support (CDS) system embedded in an electronic health record (EHR) to deliver pharmacogenomic (PGx) information to physicians. We employed a conceptual framework and measurement model to access the impact of physician characteristics (previous experience, awareness, relative advantage, perceived usefulness), technology characteristics (methods of implementation-semi-active/active, actionability-low/high) and a task characteristic (drug prescribed) on communication effectiveness (usefulness, confidence in prescribing decision), and clinical impact (uptake, prescribing intent, change in drug dosing). Physicians performed prescribing tasks using five simulated clinical case scenarios, presented in random order within the prototype PGx-CDS system. Twenty-two physicians completed the study. The proportion of physicians that saw a relative advantage to using PGx-CDS was 83% at the start and 94% at the conclusion of our study. Physicians used semi-active alerts 74-88% of the time. There was no association between previous experience with, awareness of, and belief in a relative advantage of using PGx-CDS and improved uptake. The proportion of physicians reporting confidence in their prescribing decisions decreased significantly after using the prototype PGx-CDS system (p=0.02). Despite decreases in confidence, physicians perceived a relative advantage to using PGx-CDS, viewed semi-active alerts on most occasions, and more frequently changed doses toward doses supported by published evidence. Specifically, sixty-five percent of physicians reduced their dosing, significantly for capecitabine (p=0.002) and mercaptopurine/thioguanine (p=0.03). These findings suggest a need to improve our prototype such that PGx CDS content is more useful and delivered in a way that improves physician's confidence in their prescribing decisions. The greatest increases in communication effectiveness and clinical impact of PGx-CDS are likely to be realized through continued focus on content, content delivery, and tailoring to physician characteristics.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical decision support systems; Computer-assisted drug therapy; Computerized physician order entry; Drug safety; Electronic health records; Personalized medicine; Pharmacogenomics; Physician’s practice patterns

Mesh:

Year:  2015        PMID: 25957826      PMCID: PMC4704108          DOI: 10.1016/j.jbi.2015.04.011

Source DB:  PubMed          Journal:  J Biomed Inform        ISSN: 1532-0464            Impact factor:   6.317


  38 in total

1.  Clinician's assessments of outpatient electronic medical record alert and reminder usability and usefulness requirements.

Authors:  Michael A Krall; Dean F Sittig
Journal:  Proc AMIA Symp       Date:  2002

2.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

3.  Genetic testing: a physician's perspective.

Authors:  J D Menasha; C Schechter; J Willner
Journal:  Mt Sinai J Med       Date:  2000-03

4.  PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

Authors:  James M Hoffman; Cyrine E Haidar; Mark R Wilkinson; Kristine R Crews; Donald K Baker; Nancy M Kornegay; Wenjian Yang; Ching-Hon Pui; Ulrike M Reiss; Aditya H Gaur; Scott C Howard; William E Evans; Ulrich Broeckel; Mary V Relling
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-03-11       Impact factor: 3.908

Review 5.  Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Authors:  S A Scott; K Sangkuhl; E E Gardner; C M Stein; J-S Hulot; J A Johnson; D M Roden; T E Klein; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2011-06-29       Impact factor: 6.875

6.  A computerized intervention to decrease the use of calcium channel blockers in hypertension.

Authors:  R A Rossi; N R Every
Journal:  J Gen Intern Med       Date:  1997-11       Impact factor: 5.128

7.  Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.

Authors:  S A Scott; K Sangkuhl; C M Stein; J-S Hulot; J L Mega; D M Roden; T E Klein; M S Sabatine; J A Johnson; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2013-05-22       Impact factor: 6.875

8.  Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing.

Authors:  S L Van Driest; Y Shi; E A Bowton; J S Schildcrout; J F Peterson; J Pulley; J C Denny; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2013-11-19       Impact factor: 6.875

9.  Effect of guideline based computerised decision support on decision making of multidisciplinary teams: cluster randomised trial in cardiac rehabilitation.

Authors:  Rick Goud; Nicolette F de Keizer; Gerben ter Riet; Jeremy C Wyatt; Arie Hasman; Irene M Hellemans; Niels Peek
Journal:  BMJ       Date:  2009-04-27

10.  Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: a global problem.

Authors:  Marieke J H Baars; Lidewij Henneman; Leo P Ten Kate
Journal:  Genet Med       Date:  2005 Nov-Dec       Impact factor: 8.822

View more
  16 in total

1.  Value of Genetics-informed Drug Dosing Guidance in Pregnant Women: A Needs Assessment with Obstetric Healthcare Providers at Johns Hopkins.

Authors:  Casey L Overby; Phillip Thompkins; Harold Lehmann; Christopher G Chute; Jeanne S Sheffield
Journal:  AMIA Annu Symp Proc       Date:  2018-04-16

2.  Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing.

Authors:  Susanne B Haga; Rachel Mills; Jivan Moaddeb; Nancy Allen LaPointe; Alex Cho; Geoffrey S Ginsburg
Journal:  Pharmacogenomics       Date:  2017-02-22       Impact factor: 2.533

3.  Pharmacogenomic clinical decision support design and multi-site process outcomes analysis in the eMERGE Network.

Authors:  Timothy M Herr; Josh F Peterson; Luke V Rasmussen; Pedro J Caraballo; Peggy L Peissig; Justin B Starren
Journal:  J Am Med Inform Assoc       Date:  2019-02-01       Impact factor: 4.497

4.  Integrating Pharmacogenomics into Clinical Practice: Promise vs Reality.

Authors:  Jennifer L St Sauver; Suzette J Bielinski; Janet E Olson; Elizabeth J Bell; Michaela E Mc Gree; Debra J Jacobson; Jennifer B McCormick; Pedro J Caraballo; Paul Y Takahashi; Veronique L Roger; Carolyn R Rohrer Vitek
Journal:  Am J Med       Date:  2016-05-05       Impact factor: 4.965

5.  Practical considerations for implementing genomic information resources. Experiences from eMERGE and CSER.

Authors:  Luke V Rasmussen; Casey L Overby; John Connolly; Christopher G Chute; Joshua C Denny; Robert Freimuth; Andrea L Hartzler; Ingrid A Holm; Shannon Manzi; Jyotishman Pathak; Peggy L Peissig; Maureen Smith; Marc S Williams; Brian H Shirts; Elena M Stoffel; Peter Tarczy-Hornoch; Carolyn R Rohrer Vitek; Wendy A Wolf; Justin Starren
Journal:  Appl Clin Inform       Date:  2016-09-21       Impact factor: 2.342

6.  Usability evaluation of pharmacogenomics clinical decision support aids and clinical knowledge resources in a computerized provider order entry system: a mixed methods approach.

Authors:  Emily Beth Devine; Chia-Ju Lee; Casey L Overby; Neil Abernethy; Jeannine McCune; Joe W Smith; Peter Tarczy-Hornoch
Journal:  Int J Med Inform       Date:  2014-05-09       Impact factor: 4.046

7.  User-centered design of multi-gene sequencing panel reports for clinicians.

Authors:  Elizabeth Cutting; Meghan Banchero; Amber L Beitelshees; James J Cimino; Guilherme Del Fiol; Ayse P Gurses; Mark A Hoffman; Linda Jo Bone Jeng; Kensaku Kawamoto; Mark Kelemen; Harold Alan Pincus; Alan R Shuldiner; Marc S Williams; Toni I Pollin; Casey Lynnette Overby
Journal:  J Biomed Inform       Date:  2016-07-14       Impact factor: 6.317

Review 8.  Advances in the Pharmacogenomics of Adverse Drug Reactions.

Authors:  Susannah L Collins; Daniel F Carr; Munir Pirmohamed
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

9.  Approaches to assessing the provider experience with clinical pharmacogenomic information: a scoping review.

Authors:  Nicholas J Keeling; Tyler J Dunn; John P Bentley; Sujith Ramachandran; James M Hoffman; Meagen Rosenthal
Journal:  Genet Med       Date:  2021-04-29       Impact factor: 8.822

10.  Examining perceptions of the usefulness and usability of a mobile-based system for pharmacogenomics clinical decision support: a mixed methods study.

Authors:  Kathrin Blagec; Katrina M Romagnoli; Richard D Boyce; Matthias Samwald
Journal:  PeerJ       Date:  2016-02-08       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.